Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAPIn prostate cancer, PTEN protein loss is associated with faster disease progression and reduced benefit from current standard-of-care treatments1The FDA approval reinforces Roche’s leadership in companion diagnostics and its ongoing commitment to expanding personalised healthcare to improve patient outcomes Base